New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 12, 2014
15:54 EDTSQNMSequenom targets quarterly break-even and positive cash flow in Q414
The company has established its primary financial and R&D objectives for 2014 to include: 'Achieve quarterly break-even and positive cash flow in Q414 Expand the NIPT or noninvasive prenatal testing, menu with the development of a low cost test on an alternative platform by year-end, which we expect will facilitate international access and potential future entry into the low-risk market."
News For SQNM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 23, 2015
15:46 EDTSQNMPiper Jaffray's medtech analysts hold an analyst/industry conference call
Subscribe for More Information
January 22, 2015
07:04 EDTSQNMSequenom and Cypher Genomics sign prenatal test development agreement
Subscribe for More Information
January 20, 2015
13:45 EDTSQNMIllumina rises as genomics project seen being announced in State of the Union
Subscribe for More Information
January 12, 2015
15:40 EDTSQNMSequenom Q4 preliminary results disappointing, says Piper Jaffray
Subscribe for More Information
15:27 EDTSQNMSequenom sees FY15 accessioned tests above 200K
Subscribe for More Information
15:25 EDTSQNMSequenom sees Q4 revenue $37M, consensus $44.6M
Subscribe for More Information
15:21 EDTSQNMSequenom sees FY14 revenue $151M, consensus $160.7M
Sequenom reported FY14 preliminary revenue of $151M earlier in slides for its upcoming presentation at the JP Morgan Healthcare Conference. The company said in the slides that it had reduced its cash burn from $107M in FY13 to $37M in FY14 and ended FY14 with approximately $94M in cash. The company reported FY14 NIPT accessioned tests of 162. Sequenom shares are down 1% in afternoon trading after this morning's disclosure of the conference slides.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use